Autopsy report · NCT05024058
Study of Efficacy and Safety of Ligelizumab in Adolescents and Adults With Chronic Inducible Urticaria Who Remain Symptomatic Despite Treatment With H1- Antihistamines
Cause of deathOther
“Phase III PEARL studies (CQGE031C2302 and CQGE031C2303) with ligelizumab met their primary endpoint of superiority vs placebo at Week 12 for treatment of CSU, but not versus omalizumab. Decision to discontinue was not based on safety concerns.”
Life of this trial
- Registered 3 months before it started.
- Ran for about 9 months before it stopped.
- 39 participants enrolled.
- Results were posted on the registry 1 year 1 month after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 3
- Sponsor
- Novartis Pharmaceuticals
- Sponsor type
- Industry
- Conditions
- Chronic Inducible Urticaria
- Interventions
- Ligelizumab; Placebo
- Participants
- 39
- Sites
- 24
- Countries
- Australia, Greece, Hungary, Russia, Slovakia, Spain, Taiwan, Turkey (Türkiye), United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.